Pacer Advisors
SUPN icon

Pacer Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Pacer Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14K Buy
273
+101
+59% +$5.14K ﹤0.01% 2142
2025
Q4 		$8.55K Sell
172
-190,722
-100% -$9.27M ﹤0.01% 3646
2025
Q3 		$9.12M Sell
190,894
-97,337
-34% -$3.92M 0.02% 504
2025
Q2 		$9.09M Sell
288,231
-115,397
-29% -$3.7M 0.02% 517
2025
Q1 		$13.2M Sell
403,628
-1,193,828
-75% -$42.3M 0.03% 408
2024
Q4 		$57.8M Sell
1,597,456
-155,426
-9% -$5.47M 0.12% 183
2024
Q3 		$54.7M Buy
1,752,882
+403,028
+30% +$12.6M 0.12% 199
2024
Q2 		$36.1M Buy
1,349,854
+1,348,508
+100,186% +$39.1M 0.08% 241
2024
Q1 		$45.9K Buy
1,346
+716
+114% +$21.3K ﹤0.01% 3201
2023
Q4 		$18.2K Buy
630
+327
+108% +$8.67K ﹤0.01% 3329
2023
Q3 		$8.35K Sell
303
-448,692
-100% -$13.7M ﹤0.01% 2574
2023
Q2 		$13.5M Buy
+448,995
New +$15.7M 0.05% 304
2023
Q1 		– Sell
-277,169
Closed -$9.89M – 2366
2022
Q4 		$9.89M Buy
+277,169
New +$9.63M 0.05% 341
2021
Q4 		– Sell
-90,866
Closed -$2.42M – 2225
2021
Q3 		$2.42M Sell
90,866
-5,168
-5% -$139K 0.03% 633
2021
Q2 		$2.96M Buy
96,034
+40,518
+73% +$1.24M 0.04% 503
2021
Q1 		$1.45M Buy
55,516
+37,016
+200% +$1.04M 0.03% 622
2020
Q4 		$465K Buy
18,500
+3,077
+20% +$66.2K 0.01% 999
2020
Q3 		$321K Buy
15,423
+7,406
+92% +$168K 0.01% 1112
2020
Q2 		$190K Sell
8,017
-2,083
-21% -$46K ﹤0.01% 810
2020
Q1 		$201K Sell
10,100
-10,751
-52% -$226K ﹤0.01% 414
2019
Q4 		$495K Sell
20,851
-2,452
-11% -$59.5K 0.02% 784
2019
Q3 		$640K Buy
23,303
+7,005
+43% +$208K 0.01% 944
2019
Q2 		$539K Buy
16,298
+2,240
+16% +$76.7K 0.01% 955
2019
Q1 		$493K Buy
14,058
+2,098
+18% +$78.1K 0.01% 578
2018
Q4 		$397K Buy
+11,960
New +$514K 0.01% 162

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pacer Advisors's SUPN Position: Q1 2026 in Review

Pacer Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 59% in Q1 2026, buying an estimated $5.14K and bringing the position to 273 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #2142.

Pacer Advisors first reported a position in SUPN in Q4 2018 and has held it in 25 quarters since. The position peaked at $57.8M in Q4 2024. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Pacer Advisors held 273 shares of Supernus Pharmaceuticals worth $14K as of Q1 2026.
  • Pacer Advisors bought 101 Supernus Pharmaceuticals shares in Q1 2026, an estimated $5.14K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Pacer Advisors's portfolio in Q1 2026, its #2142 holding.
  • Pacer Advisors first reported a position in Supernus Pharmaceuticals in Q4 2018 and has held it in 25 quarters since.
  • Pacer Advisors's Supernus Pharmaceuticals position peaked at $57.8M in Q4 2024.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.